Thanks to the significantly improved outcome during studies, novel therapy opportunities targeting CD19, CD20, CD22 and CD52 surface antigens have become more important in ALL treatment over the past years (Table 2). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.